børresen-dale: molecular evolution under neoadjuvant chemotherapy
Published 8 years ago • 64 plays • Length 0:53Download video MP4
Download video MP3
Similar videos
-
7:18
molecular evolution of breast cancer during neoadjuvant chemotherapy
-
36:42
evaluation of breast specimens after neoadjuvant chemotherapy
-
17:58
state of the art - neoadjuvant chemotherapy becoming standard of care in mibc?
-
2:12
what is neoadjuvant therapy?
-
3:20
what is neoadjuvant therapy? | dana-farber cancer institute
-
10:26
indications for neoadjuvant therapy in breast cancer therapy
-
23:05
total neoadjuvant therapy in rectal cancer in the community setting | 2022 evolution conference
-
1:31
neoadjuvant chemotherapy
-
6:27
how to use neoadjuvant therapies in breast cancer?
-
3:45
neoadjuvant chemotherapy - breast cancer
-
3:51
neoadjuvant chemotherapy utilization and perioperative morbidity
-
1:15
dll3, a new biomarker for neuroendocrine tumors of the lung
-
27:03
triple negative breast cancer: predictive and prognostic biomarkers for neo/adjuvant therapy
-
55:42
evolution of surgical care in breast cancer
-
4:50
randomized phase iii clinical trial of neoadjuvant intravesical mitomycin c treatment
-
1:54
the role of dna repair in triple negative breast cancer
-
1:59
dr. von minckwitz on pathologic complete response in breast cancer
-
1:56
breast cancer and need of chemotherapy
-
7:22
the effect of neoadjuvant chemoradiation on anastomotic leak & additional 30 day morbidity or mortal